Thomas Rolland Fleming
#106,317
Most Influential Person Now
Thomas Rolland Fleming's AcademicInfluence.com Rankings
Thomas Rolland Flemingmedical Degrees
Medical
#1336
World Rank
#1662
Historical Rank
Oncology
#57
World Rank
#60
Historical Rank
Thomas Rolland Flemingphilosophy Degrees
Philosophy
#4309
World Rank
#6782
Historical Rank
Logic
#1801
World Rank
#2644
Historical Rank
Download Badge
Medical Philosophy
Thomas Rolland Fleming's Degrees
- Doctorate Medicine Harvard University
- PhD Biochemistry Stanford University
Why Is Thomas Rolland Fleming Influential?
(Suggest an Edit or Addition)Thomas Rolland Fleming's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (2001) (10106)
- A multiple testing procedure for clinical trials. (1979) (2997)
- Prevention of HIV-1 infection with early antiretroviral therapy. (2011) (2213)
- Sildenafil citrate therapy for pulmonary arterial hypertension. (2005) (1939)
- Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. (1990) (1793)
- Counting Processes and Survival Analysis (1991) (1420)
- Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) (2004) (1127)
- Martingale-based residuals for survival models (1990) (1065)
- One-sample multiple testing procedure for phase II clinical trials. (1982) (978)
- Prognosis in primary biliary cirrhosis: Model for decision making (1989) (798)
- Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. (1989) (667)
- Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016) (623)
- High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. (1985) (543)
- Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. (2008) (513)
- An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. (1993) (434)
- Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial (1998) (405)
- Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. (1992) (404)
- A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. (1985) (397)
- Biomarkers and surrogate endpoints in clinical trials (2012) (392)
- Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. (1995) (364)
- Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. (1995) (353)
- Designs for group sequential tests. (1984) (314)
- Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data. (1989) (286)
- Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037). (1987) (269)
- Pediatric pulmonary hypertension. (2013) (257)
- Primary sclerosing cholangitis: refinement and validation of survival models. (1992) (248)
- Estimating the proportion of treatment effect explained by a surrogate marker. (1997) (247)
- End points and clinical trial design in pulmonary arterial hypertension. (2004) (246)
- Surrogate endpoints and FDA's accelerated approval process. (2005) (238)
- Data Monitoring Committees in Clinical Trials: A Practical Perspective (2002) (229)
- Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. (2011) (223)
- Efficacy of liver transplantation in patients with primary biliary cirrhosis. (1989) (221)
- A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. (1982) (219)
- Modified Kolmogorov-Smirnov Test Procedures with Application to Arbitrarily Right-Censored Data (1980) (216)
- Considerations in boosting COVID-19 vaccine immune responses (2021) (205)
- A Nonparametric Method for Dealing with Mismeasured Covariate Data (1991) (203)
- Parameter estimation following group sequential hypothesis testing (1990) (200)
- Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. (1999) (187)
- Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. (2012) (185)
- Data Monitoring Committees in Clinical Trials (2002) (175)
- Current issues in non‐inferiority trials (2008) (173)
- A class of hypothesis tests for one and two sample censored survival data (1981) (169)
- Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. (1995) (168)
- Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study (2014) (167)
- Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. (1994) (166)
- [Pediatric pulmonary hypertension]. (2014) (164)
- Trial of penicillamine in advanced primary biliary cirrhosis. (1985) (154)
- Symmetric group sequential test designs. (1989) (145)
- Perspective: validating surrogate markers--are we being naive? (1997) (137)
- Cyclophosphamide plus cis-Platinum in Combination: Treatment Program for Stage III or IV Ovarian Carcinoma (1982) (137)
- New trial designs and potential therapies for pulmonary artery hypertension. (2013) (129)
- Antiretroviral Therapy for Adult HIV-lnfected Patients: Recommendations From a State-of-the-Art Conference (1993) (121)
- Survival Analysis in Clinical Trials: Past Developments and Future Directions (2000) (120)
- Monitoring of clinical trials: issues and recommendations. (1993) (117)
- A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. (1985) (116)
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015 (2016) (110)
- Supremum versions of the log-rank and generalized wilcoxon statistics (1987) (110)
- Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease. (1979) (108)
- Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. (1993) (107)
- Extramural cross‐validation of the mayo primary biliary cirrhosis survival model establishes its generalizability (1989) (106)
- Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial (2019) (106)
- Evaluation of response criteria in advanced lung cancer (1979) (104)
- Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. (2008) (103)
- A paired prentice-Wilcoxon test for censored paired data (1987) (103)
- A randomized double-blind trial of iseganan in prevention of ventilator-associated pneumonia. (2006) (100)
- Nonparametric estimation of the survival distribution in censored data (1984) (98)
- Single metastasis to the brain. Surgical treatment in 122 consecutive patients. (1981) (96)
- Radical retropubic prostatectomy and pelvic lymphadenectomy for high‐stage cancer of the prostate (1981) (95)
- Surrogate Endpoints in Clinical Trials (1996) (94)
- Auxiliary outcome data and the mean score method (1994) (93)
- Weighted Kaplan‐Meier Statistics: Large Sample and Optimality Considerations (1991) (93)
- Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A southwest oncology group study (1995) (92)
- Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid (1994) (88)
- Randomized study of systemic chemotherapy following complete excision of nonosseous sarcomas. (1984) (86)
- Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. (2012) (86)
- Course of localized adenocarcinoma of the prostate treated by radical prostatectomy (1983) (85)
- A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. (2007) (82)
- 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group Study. (1987) (78)
- Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials (2020) (77)
- Policies for study monitoring and interim reporting of results. (1987) (74)
- Some design issues in trials of microbicides for the prevention of HIV infection. (2004) (72)
- Some essential considerations in the design and conduct of non-inferiority trials (2011) (71)
- Conducting Clinical Research During the COVID-19 Pandemic: Protecting Scientific Integrity. (2020) (71)
- Pulmonary resection for metastatic nonosteogenic sarcoma (1979) (70)
- Definitive radiation therapy for prostatic carcinoma: Mayo clinic experience. (1980) (69)
- Safety and toxicity of nonoxynol-9 gel as a rectal microbicide. (1999) (68)
- Evaluating Therapeutic Interventions: Some Issues and Experiences (1992) (67)
- Addressing Missing Data in Clinical Trials (2011) (65)
- Proceedings of the First Seattle Symposium in Biostatistics: Survival Analysis (1997) (64)
- A Phase III, Randomized, Double-blind, Placebo-controlled, Multinational Trial of Iseganan for the Prevention of Oral Mucositis in Patients Receiving Stomatotoxic Chemotherapy (PROMPT-CT Trial) (2003) (63)
- Clinical Trials: Discerning Hype From Substance (2010) (62)
- Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks. (2020) (59)
- Design and interpretation of equivalence trials. (2000) (59)
- Evaluation of active control trials in AIDS. (1990) (58)
- Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary. (1997) (57)
- A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. (2004) (56)
- Issues in using progression-free survival when evaluating oncology products. (2009) (55)
- Counting Processes and Survival Analysis: Fleming/Counting (2005) (55)
- Placebo-Controlled Trials of Covid-19 Vaccines - Why We Still Need Them. (2020) (54)
- Model misspecification in proportional hazards regression (1995) (53)
- Issues in noninferiority trials: the evidence in community-acquired pneumonia. (2008) (53)
- Evaluating rivaroxaban for nonvalvular atrial fibrillation--regulatory considerations. (2011) (53)
- The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials. (1995) (52)
- Surrogate markers in aids and cancer trials (1994) (52)
- Risk of local urethral recurrence after radical cystectomy for bladder cancer. (1984) (51)
- Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for adenocarcinoma confined to the prostate. (1984) (51)
- Maintaining confidentiality of interim data to enhance trial integrity and credibility (2008) (49)
- Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer. (1983) (47)
- Approaches to monitoring clinical trials. (1989) (45)
- Data monitoring committees: Promoting best practices to address emerging challenges (2017) (44)
- Dianhydrogalactitol and radiation therapy. Treatment of supratentorial glioma. (1979) (43)
- Standard versus adaptive monitoring procedures: a commentary (2006) (43)
- Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A southwest oncology group study (1993) (42)
- Surrogate markers in AIDS and cancer trials. (1994) (42)
- Identifying and addressing safety signals in clinical trials. (2008) (42)
- Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia (2019) (42)
- Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study. (1992) (42)
- Treatment evaluation in active control studies. (1987) (41)
- Long-term treatment with sildenafil citrate in pulmonary arterial hypertension (2008) (41)
- Recommended changes to oncology clinical trial design: revolution or evolution? (2008) (40)
- Cyclophosphamide, adriamycin, and cis‐diamminedichloroplatinum (II) in the treatment of patients with advanced head and neck cancer (1981) (39)
- Nonparametric Estimation for Nonhomogeneous Markov Processes in the Problem of Competing Risks (1978) (39)
- A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas: a Southwest Oncology Group study. (1991) (37)
- Adaptive Methods: Telling “The Rest of the Story” (2010) (36)
- Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas. (1985) (36)
- Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. (1994) (35)
- Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension (Annals of Internal Medicine (2008) 149 (521-530)) (2008) (35)
- Effects on overviews of early stopping rules for clinical trials. (1987) (33)
- Considerations for monitoring and evaluating treatment effects in clinical trials. (1984) (33)
- Objective response rate as a surrogate end point: a commentary. (2005) (32)
- Asymptotic Distribution Results in Competing Risks Estimation (1978) (29)
- Liability issues for data monitoring committee members (2004) (29)
- Evaluation of alternating chemotherapy and sites and extent of disease in extensive small cell lung cancer (1981) (28)
- Testing in a Prespecified Subgroup and the Intent-to-Treat Population (2012) (27)
- A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study. (1990) (27)
- The independent statistician for data monitoring committees (2004) (27)
- Erratum: Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 (The Lancet (2016) 388(10053) (1775–1812)(S0140673616314702)(10.1016/S0140-6736(16)31470-2)) (2017) (27)
- Randomized trial of thoracic irradiation plus combination chemotherapy for unresectable adenocarcinoma and large cell carcinoma of the lung. (1979) (27)
- Adjuvant continuous infusion 5-FU, whole-abdominal radiation, and tumor bed boost in high-risk stage III colon carcinoma: a Southwest Oncology Group Pilot study. (1995) (25)
- Using surrogate failure time data to increase cost effectiveness in clinical trials (1993) (24)
- Chemotherapy for advanced head and neck cancer with the combination adriamycin, cyclophosphamide, and cis‐diamminedichloroplatinum (II): Preliminary assessment of a one‐day vs. three‐day drug regimen (1981) (24)
- Procedures for Serial Testing in Censored Survival Data (1984) (23)
- Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005. (2008) (22)
- Data Monitoring Committees: Current issues (2018) (22)
- Statistical issues in the design of HIV vaccine trials. (1995) (22)
- Statistical considerations for the HPTN 052 Study to evaluate the effectiveness of early versus delayed antiretroviral strategies to prevent the sexual transmission of HIV-1 in serodiscordant couples. (2012) (22)
- Phase II study of 5‐fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A southwest oncology group study (1995) (21)
- Phase II study of pibenzimol in pancreatic cancer (1991) (21)
- Historical controls, data banks, and randomized trials in clinical research: a review. (1982) (21)
- Weighted Mean Survival Test Statistics: a Class of Distance Tests for Censored Survival Data (1997) (20)
- Surgical adjuvant therapy of rectal cancer. (1988) (20)
- Executive summary: workshop on issues in the design and conduct of clinical trials of antibacterial drugs in the treatment of community-acquired pneumonia. (2008) (20)
- Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. (2014) (20)
- Surrogate end points in cardiovascular disease trials. (2000) (20)
- Data monitoring committees and capturing relevant information of high quality. (1993) (19)
- Enhancing Trial Integrity by Protecting the Independence of Data Monitoring Committees in Clinical Trials (2014) (19)
- Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial (2022) (19)
- Protecting the confidentiality of interim data: Addressing current challenges (2015) (19)
- When Can Intermediate Outcomes Be Used as Surrogate Outcomes? (2020) (18)
- Insights from monitoring the CPCRA didanosine/zalcitabine trial. Terry Beirn Community Programs for Clinical Research on AIDS. (1995) (18)
- A phase II multi‐institutional trial of low‐dose N‐(phosphonacetyl)‐L‐aspartate and high‐dose 5‐fluorouracil as a short‐term infusion in the treatment of adenocarcinoma of the pancreas. A southwest oncology group study (1991) (17)
- FLEMING, T. R.; HAKRINGTON, D. P.: Counting Processes and Survival Analysis. Wiley (1992) (17)
- Appropriateness of Hydroxyethylcellulose Gel as a Placebo Control in Vaginal Microbicide Trials: A Comparison of the Two Control Arms of HPTN 035 (2013) (17)
- Study Design Considerations for Evaluating Efficacy of Systemic Preexposure Prophylaxis Interventions (2013) (16)
- Statistical Evaluation and Analysis of Regional Interactions: The PLATO Trial Case Study (2013) (16)
- Comparison of combination chemotherapy programs in advanced adenocarcinoma-large cell carcinoma of the lung: a North Central Cancer Treatment Group study. (1984) (16)
- Interpretation of Subgroup Analyses in Clinical Trials (1995) (16)
- Estimation for discrete time nonhomogeneous Markov chains (1978) (15)
- Surgery for Recurrent Colon Cancer (1999) (15)
- Phase II study of fludarabine phosphate in previously untreated patients with hepatoma: a Southwest Oncology Group Study. (1987) (15)
- Evaluating interventions for Ebola: The need for randomized trials (2016) (14)
- Guidelines for reporting clinical trials. (1988) (14)
- A role of cis-dichlorodiammineplatinum(II) in squamous cell lung cancer. (1980) (14)
- Phase II evaluation of PALA in patients with metastatic lung cancer. (1981) (14)
- Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials (2020) (13)
- COVID-19 vaccine trials: The use of active controls and non-inferiority studies (2021) (13)
- A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer. (1985) (13)
- A Simulation Study Evaluating Bio-Creep Risk in Serial Noninferiority Clinical Trials for Preservation of Effect (2015) (13)
- Adaptive Test for Testing the Difference in Survival Distributions (2003) (12)
- Treatment of HIV infection--progress in perspective. (1992) (12)
- High incidence of coagualopathy in phase II studies of recombinant tumor necrosis factor in advanced pancreatic and gastric cancers. (1992) (12)
- Phase II study of fludarabine phosphate in previously untreated patients with colorectal carcinoma: a Southwest Oncology Group Study. (1987) (11)
- A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated (2021) (11)
- Phase II evaluation of recombinant gamma-interferon in patients with advanced pancreatic carcinoma: a Southwest Oncology Group study. (1990) (10)
- Interim analyses in clinical trials. (1990) (10)
- Insights on the Robust Variance Estimator under Recurrent‐Events Model (2011) (10)
- A randomized trial of two schedules of trimetrexate versus 5‐fluorouracil in advanced colorectal cancer: a Southwest Oncology Group Study (1995) (10)
- Noninferiority trials: clinical understandings and misunderstandings. (2013) (10)
- Large sample properties of some survival estimators in heterogeneous samples (1997) (10)
- Adjusting for Unknown Bias in Noninferiority Clinical Trials (2013) (10)
- Bias and trials stopped early for benefit. (2010) (10)
- [Evaluating Therapeutic Interventions: Some Issues and Experiences]: Rejoinder (1992) (10)
- Issues in the design of clinical trials: insights from the trastuzumab (Herceptin) experience. (1999) (10)
- Achieving effective informed oversight by DMCs in COVID clinical trials (2020) (10)
- Institutional Responsibility and the Flawed Genomic Biomarkers at Duke University: A Missed Opportunity for Transparency and Accountability (2017) (9)
- Challenges in the Design of HIV Prevention Trials in the United States (2010) (8)
- Residuals for Survival Analysis (2005) (7)
- Phase II study of pibenzimol in pancreatic cancer. A Southwest Oncology Group study. (1991) (7)
- Cisplatin, vinblastine, and mitoguazone in squamous cell carcinoma of the esophagus: a Southwest Oncology Group Study. (1987) (7)
- An evaluation of low-dose cisplatin as part of combined modality therapy of limited small cell lung cancer. (1981) (7)
- A multi-national, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of BMN 110 treatment for mucopolysaccharidosis IVA (Morquio syndrome type A) (2013) (7)
- Phase II trial of recombinant DNA gamma-interferon in advanced colorectal cancer: a Southwest Oncology Group study. (1991) (7)
- Identifying and Addressing Safety Signals in Clinical Trials: Some Issues and Challenges (2013) (6)
- Phase II evaluation of maytansine in patients with advanced head and neck cancer. (1979) (5)
- 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
- Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study (1990) (5)
- Phase IIb double-blind, randomized, placebo-controlled trials for the efficacy and safety of sorafenib in patients (pts) with metastatic or locally advanced breast cancer (BC): Review of the Trials to Investigate the Effects of Sorafenib in BC (TIES) program. (2009) (5)
- A platform trial design for preventive vaccines against Marburg virus and other emerging infectious disease threats (2022) (5)
- Statistical, Philosophical and Ethical Issues in Data Monitoring (2003) (4)
- COVID-19 vaccine trials: The potential for “hybrid” analyses (2021) (4)
- Phase II trial of trimetrexate in advanced esophageal cancer: A southwest oncology group study (1995) (4)
- Bias and Trials Stopped Early for Benefit. Authors' reply (2010) (4)
- Weighted Logrank Statistics (2011) (4)
- Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group Study. (1987) (4)
- Reply to Skoler et al. and to Stein and Susser (2005) (4)
- Phase II evaluation of triazinate in patients with metastatic lung cancer. (1980) (4)
- Development Paths for New Drugs with Large Treatment Effects Seen Early (2011) (4)
- Performing serial testing of treatment effects. (1982) (4)
- Chemotherapy response as a prognosticator for survival in patients with limited squamous cell lung cancer treated with combined chemotherapy and radiotherapy. (1980) (3)
- Assessing Effects on Long-term Survival after Early Termination of Randomized Trials (1999) (3)
- Estimation for branching processes with varying and random environments (1978) (3)
- Phase II trial of echinomycin in advanced colorectal cancer. A Southwest Oncology Group study. (1991) (3)
- Chemotherapeutic sensitivity of minimal residual disease following surgical excision of ovarian carcinoma. (1978) (3)
- Viral load and response to treatment of HIV. (1996) (3)
- Surrogate endpoints. (1997) (3)
- Phase II evaluation of chlorozotocin in advanced bronchogenic carcinoma. (1979) (3)
- Patient-Reported Outcomes in Oncology Clinical Trials: Stakeholder Perspectives from the Accelerating Anticancer Agent Development and Validation Workshop 2019. (2020) (3)
- Phase II study of trimetrexate in previously untreated patients with hepatocellular carcinoma (1993) (2)
- Phase II trial of echinomycin in advanced colorectal cancer (1991) (2)
- Phase II trial of amonafide in advanced pancreas cancer (1993) (2)
- A treatment program for stage III and IV ovarian cancer — Cyclophosphamide versus cyclophosphamide and Cis-platinum (1980) (2)
- Appendix D: Data (2011) (2)
- FDA/Arthritis Foundation osteoarthritis drug development workshop recap: Assessment of long-term benefit. (2022) (2)
- Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. (2013) (2)
- A Martingale Central Limit Theorem (2011) (2)
- Monitoring clinical trials. (1998) (2)
- Long-Term Oral Sildenafil Added To Intravenous Epoprostenol Therapy Improves Outcomes In Patients With Pulmonary Arterial Hypertension (2010) (2)
- A Conversation about COVID-19 with Biostatisticians and Epidemiologists (2020) (2)
- A phase II study of chemotherapy of metastatic colorectal carcinoma with 5-fluorouracil plus cisplatin (1991) (1)
- Regulatory Considerations for the Operation of Data Monitoring Committees (2003) (1)
- Discussion: The role, position, and function of the FDA-The past, present, and future. (2017) (1)
- A note on efficiencies for estimators in varying environments (1979) (1)
- Phase II trial of bisantrene in hepatocellular carcinoma: a Southwest Oncology Group Study. (1987) (1)
- VM-26 in colorectal carcinoma: A Southwest Oncology Group study (1990) (1)
- Department of Error (2017) (1)
- Phase II study of fludarabine phosphate in previously untreated patients with hepatoma (1987) (1)
- Statistical properties of estimators for continuous time Markov branching processes with varying and random environments (1982) (1)
- Appendix A: The Data Monitoring Committee Charter (2003) (1)
- A phase II study of chemotherapy of metastatic colorectal carcinoma with 5-fluorouracil plus cisplatin. A Southwest Oncology Group study. (1991) (1)
- Simultaneous Use of Weighted Logrank and Standardized Kaplan-Meier Statistics (2006) (1)
- Proceedings of the Fourth Seattle Symposium in Biostatistics: Clinical Trials (2013) (1)
- Trial designs for evaluating combination HIV prevention approaches (2020) (1)
- Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-Fluorouracil in advanced gastric adenocarcinoma (1996) (1)
- A drug is effective if better than a harmless control (2005) (1)
- Reliably Assessing Duration of Protection for Coronavirus Disease 2019 Vaccines (2021) (1)
- Designing & Conducting Trials to Reliably Evaluate HIV Prevention Interventions (2019) (1)
- Data Monitoring Committee Interactions with Other Trial Components or Related Groups (2003) (1)
- High incidence of coagulopathy in phase II studies of recombinant tumor necrosis factor in advanced pancreatic and gastric cancers (1992) (1)
- SURGERY FOR RECURRENT COLON CANCER. AUTHORS' REPLY (1999) (0)
- Statistics for the Two-Sample Survival Analysis Problem Based on Product Limit Estimators of the Survival Functions. (1986) (0)
- Guidelines for the reporting of clinical trials. (1988) (0)
- Cytoxan adriamycin cis platinum vs. methotrexate adriamycin cytoxan 1 2 chloroethyl 3 cyclohexyl 1 nitroso urea in advanced adeno carcinoma and large cell carcinoma of the lung (1981) (0)
- A CLASS OF RANK TEST PROCEDURES FOR CENSORED SURVIVAL DATA by DAVID P. HARRINGTON and THOMAS R. FLEMING (2000) (0)
- 74. Surrogate Endpoints (2014) (0)
- Alternative Trial Designs: Conference Summary (1995) (0)
- The Counting Process and Martingale Framework (2011) (0)
- Phase II trial of bisantrene in hepatocellular carcinoma (1987) (0)
- Innovations in Pediatric Therapeutics Development: Principles for the Use of Bridging Biomarkers in Pediatric Extrapolation (2022) (0)
- Confidentiality Issues Relating to the Data Monitoring Committee (2003) (0)
- Cyclophosphamide and Cisplatin vs Hexamethylmelamine, Cyclophosphamide, Doxorubicin, Cisplatin in Combination as Initial Chemotherapy for Stage III and IV Ovarian Carcinoma (1986) (0)
- Independence of the Data Monitoring Committee: Avoiding Conflicts of Interest (2003) (0)
- Appendix A: Some Results from Stieltjes Integration and Probability Theory (2011) (0)
- Discussion of paper by C. B. Begg (1990) (0)
- An FDA perspective on antiarrhythmic drugs in Phase II trials (2000) (0)
- Monitoring clinical trials in infectious diseases (2021) (0)
- Testing AIDS drugs without placebos [1] (2005) (0)
- Composition of a Data Monitoring Committee (2003) (0)
- Large Sample Results for the Kaplan‐Meier Estimator (2011) (0)
- Censored Data Regression Models and Their Application (2011) (0)
- Appendix B: An Introduction to Weak Convergence (2011) (0)
- Data Monitoring Committee Meetings (2003) (0)
- Finite Sample Moments and Large Sample Consistency of Tests and Estimators (2011) (0)
- An intuitive non-rank-based statistic for the two-sample censored-data survival analysis problem (1986) (0)
- CLINICAL TRIALS IN BIOTECHNOLOGY: A PERSPECTIVE FROM THE PHARMACEUTICAL INDUSTRY (1996) (0)
- Cardiovascular safety trials of antidiabetic therapies to treat type 2 diabetes: perhaps asking the wrong question? (2019) (0)
- Phase II trial of menogaril in adenocarcinoma of the pancreas. A Southwest Oncology Group study. (1991) (0)
- Determining When a Data Monitoring Committee is Needed (2003) (0)
- Local Square Integrable Martingales (2011) (0)
- Responsibilities of the Data Monitoring Committee and Motivating Illustrations (2003) (0)
- No, Not Another IRB (2003) (0)
- Distribution Theory for Proportional Hazards Regression (2011) (0)
- 5-Day vinblastine infusion for pancreatic adenocarcinoma (1990) (0)
- HIV viral load in rectal mucosa and plasma (1997) (0)
- Are HIV prevention programs effective in addressing rising HIV/AIDS rates among Central Asian labor migrants? (2011) (0)
- Appendix E: Exercises (2011) (0)
- Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seek. (2023) (0)
- Response to the letter from Korn et al (2008) (0)
- Concurrent 5-FU chemotherapy and whole abdominal irradiation in patients with stage C2 extrapelvic colon cancer (1992) (0)
- An Analysis of the Carry Trade: Historical and Empirical Evidence from the Japanese Yen and Australian Dollar Currency Pair (2014) (0)
- AN INVESTIGATION INTO THE OPERATING CHARACTERISTICS OF SOME TWO-SAMPLE NONPARAMETRIC TEST PROCEDURES USED FOR CENSORED SURVIVAL DATA by THOMAS R. FLEMING and DAVID P. HARRINGTON (2000) (0)
- "(2006), A16. Brody, Baruch A. The Ethics of Biomedical Research: An International Perspective. New York: Oxford University Press, 1998. Capron, Alexander M." Experimentation with Human Beings: Light or Only Shadows?" Yale Journal of Health Policy, Law and (2008) (0)
- Estimating the distribution of Quality-Adjusted Life with censored data (2000) (0)
- Eight Years of Experience on a DSMB for HIV/AIDS Trials (1994) (0)
- A novel event-free survival endpoint in locally advanced pancreatic cancer (2021) (0)
- Appendix C: The Martingale Central Limit Theorem: Some Preliminaries (2011) (0)
- [New trial designs and potential therapies for pulmonary artery hypertension]. (2014) (0)
- 5-day vinblastine infusion for pancreatic adenocarcinoma. A phase II Southwest Oncology Group study. (1990) (0)
- Phase II evaluation of esorubicin (4′ deoxydoxorubicin) in pancreatic adenocarcinoma: A Southwest Oncology Group study (1990) (0)
- Evaluating group-sequential non-inferiority clinical trials following interim stopping: The HIV Prevention Trials Network 083 trial (2022) (0)
- Phase II trial of menogaril in adenocarcinoma of the pancreas (1991) (0)
- The Applied Setting (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Thomas Rolland Fleming?
Thomas Rolland Fleming is affiliated with the following schools:
